BPC-157 vs Tesamorelin
A comprehensive, data-driven comparison of BPC-157 (Body Protection Compound-157) and Tesamorelin (Egrifta). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | BPC-157 Body Protection Compound-157, PL 14736 | Tesamorelin Egrifta, TH9507 |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | FDA Approved |
| Category | Recovery & Healing | Growth Hormone |
| Primary Use | Tissue healing and injury recovery | HIV-associated lipodystrophy |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $50 - $120/mo | $200 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 250-500mcg daily | 2mg daily |
| Frequency | Daily | Daily |
| Mechanism | Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth factors, and accelerates tissue repair | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Low | High |
| Clinical Trial Phase | N/A | Approved |
Key Differences
- 1Tesamorelin is FDA-approved, while BPC-157 is currently category 2 (pending reclassification).
- 2BPC-157 is generally more affordable ($50 - $120/mo) compared to Tesamorelin ($200 - $1,500/mo).
- 3Tesamorelin has high-quality evidence, while BPC-157 has low-quality evidence.
- 4They belong to different categories: BPC-157 (Recovery & Healing) vs Tesamorelin (Growth Hormone).
Which Is Better For...
Tesamorelin
Those seeking an FDA-approved treatment with established safety data
BPC-157
More budget-friendly option with lower monthly costs
BPC-157
Fewer commonly reported side effects
Tesamorelin
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| BPC-157 | $50 - $120/mo | Category 2 (pending reclassification) | Various research labs |
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
BPC-157 works via Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth. Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. They differ in FDA approval status, efficacy data, and cost.
BPC-157 typically costs $50 - $120/mo, while Tesamorelin costs $200 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
BPC-157 is not FDA-approved (Category 2 (pending reclassification)). Tesamorelin is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of BPC-157 include Injection site discomfort, Mild headache, Dizziness. Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
BPC-157 is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. Although not FDA-approved, it has gained significant attention in research a...
View Full BPC-157 GuideTesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between BPC-157 and Tesamorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.